MenoSerene
Natural health product licensed in Canada
- Licence holder
- BioAid Health Products Inc.
- NPN or DIN-HM
- 80032703
- Status
- Inactive licence
- Licence date
- 11 June 2012
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Vitex agnus-castus L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Glycine max. (L.) Merr.: La portion journalière recommandée ne doit pas conduire à une ingestion d'isoflavones supérieure à 1 mg/kg de poids corporel (exprimés comme aglycone du composant principal). L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Vitex agnus-castus Source : Fruit Extraction ratio : 4:1 Dry plant equivalent : 200 mg Potency : 0.6 % Aucubin | 50 mg | Not calculated |
| Angelica sinensis Source : Racine Extraction ratio : 10:1 Dry plant equivalent : 500 mg Potency : 1 % Ligustilide | 50 mg | Not calculated |
| Cimicifuga racemosa Source : Racine Extraction ratio : 15:1 Dry plant equivalent : 750 mg Potency : 2.5 % Triterpenoids | 50 mg | Not calculated |
| Glycine max Source : Fève de soya Potency : 15.5 mg ÉAI Genistein | Not specified | Not calculated |
| Glycine max Source : Fève de soya Potency : 3.75 mg ÉAI Genistin | Not specified | Not calculated |
Non-medicinal ingredients
Pyrus Malus (apple) fiber, Hypromellose, Stéarate de magnésium, L-leucine, Pullulane
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Femmes en postménopause | Not specified | 3 Capsule | 1 Tous les jours |
| Femmes en postménopause | Not specified | minimum: 1 Capsule ; maximum: 2 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
MenoSerene helps to attenuate/reduce bone mineral density (BMD) loss in post-menopausal women when used in conjunction with adequate amounts of calcium and vitamin D. It may also reduce severe and frequent menopausal symptoms.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80032703
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.